Guardant Health

Conquering Cancer With Data

[Guardant Health @GuardantHealth]

We’re building something new at Guardant Health, and it starts with #People.

Introducing Guardant Health Talent Communities, a way to stay in touch and be among the first to hear about new, purpose-driven opportunities aligned to your interests. This approach goes beyond hiring for today, it’s about shaping strong, future-ready talent networks to help advance our mission to conquer cancer with data.

Join our Talent Community to stay connected and see what’s next: https://t.co/om3It42Jjf

[MD+DI @MDDIonline]

"The best test is the test that gets done." ACS adds Guardant's Shield blood test to colorectal cancer screening guidelines, expanding options for the 50M+ Americans not up to date on CRC screening. What clinicians need to know: https://t.co/1ODI7X5GJ4

[Guardant Health @GuardantHealth]

Today, we honor cancer survivors—the resilience, strength and courage of those who have fought and continue to fight cancer inspire us every day.

#NationalCancerSurvivorsDay #NCSD #CancerSurvivorsDay

[Guardant Health @GuardantHealth]

The next evolution of liquid biopsy is here.

Discover how the FDA-approved Guardant360® Liquid CDx is driving precision oncology into the future at #ASCO26 booth 31093.

[Guardant Health @GuardantHealth]

Screening participation remains one of the biggest challenges in tackling today's rising #ColorectalCancer rates.

@CNN's latest coverage highlights why expanding screening options matters — and why the inclusion of blood-based tests like Shield™ in updated ACS guidelines is such an important step forward.

[CNN @CNN]

The American Cancer Society is adding some new testing options to its screening guideline for colorectal cancers – and for the first time, that includes a blood test. https://t.co/tHDkg3v74P

[Guardant Health @GuardantHealth]

As #ASCO26 gets underway, we’re set to share 38 abstracts showcasing advances in methylation-based tumor classification, liquid biopsy technology, and the expanding clinical utility of our InfinityAI-powered portfolio as the #GlobalOncology community comes together in Chicago.

Details: https://t.co/wnCyX3i8s9

[Guardant Health @GuardantHealth]

In a major update published this morning, @AmericanCancer now includes our Shield™ blood test in its #ColorectalCancer screening guidelines — recognizing blood-based screening as a new option to help expand access and increase screening participation.

More than 50 million eligible Americans are still not up to date with CRC screening, despite established screening methods being available for decades. The updated guidelines acknowledge the opportunity for blood-based screening to help reach people who might otherwise go unscreened and close the screening gap.

More: https://t.co/2v56RrRLjD

[Guardant Health @GuardantHealth]

Cancer care is evolving — and at Guardant Health, we’re continuing to advance what’s possible with comprehensive genomic profiling.

We pioneered the first FDA-approved comprehensive liquid biopsy. Now, we’re introducing the next evolution: Guardant360® Liquid CDx, the largest FDA-approved liquid biopsy panel, featuring a 100x expanded genomic and epigenomic footprint designed to deliver a more complete, actionable view of cancer from just a blood draw.

Details: https://t.co/EJivlCruTY

[Guardant Health @GuardantHealth]

@Spokavriel @PreventionMag @Spokavriel We can confirm Patrick Dempsey is not Dale. Thanks for the interest in our campaign and for watching so closely!

[Guardant Health @GuardantHealth]

We’re looking forward to joining the oncology nursing community this week at #ONSCongress 2026. Stop by booth 743 to connect with our team and learn how ctDNA testing and liquid biopsy insights are helping inform #PrecisionOncology.

We’ll also host two sessions of our educational event, From detection to decision: the role of ctDNA in oncology care, during the meeting:

Thursday, May 14 | 6:00PM CT: https://t.co/4fuWkUZh1m
Friday, May 15 | 6:00PM CT: https://t.co/X1ufD9ZN3e

[Guardant Health @GuardantHealth]

At #MIGlobal, our chairman and co-CEO Helmy Eltoukhy discussed the next wave of health innovation and how advances in diagnostics, AI, and large-scale data are accelerating a shift toward earlier, more actionable cancer care.

As Helmy shared, diagnostics already inform the majority of medical decisions, yet the healthcare system still invests far more heavily in treating disease after it progresses than detecting it earlier.

The future of cancer care has to look different. Helmy shared a powerful example of what happens when technology compounds and the kind of progress that can help bend the healthcare cost curve.

Watch the full session: https://t.co/su0iVzguTp

[Guardant Health @GuardantHealth]

Yesterday, we shared our first quarter 2026 financial results, with 48% year-over-year revenue growth driven by strong performance across our Oncology and Screening businesses.

This included significant growth across Guardant360® Liquid and Guardant360® Tissue testing, strong receptivity to our expansion into therapy response monitoring with Guardant Reveal®, and increasing Shield™ volumes as we continue working to bring precision oncology and cancer screening solutions to more patients.

Details: https://t.co/hvaJK4qaMR

[Guardant Health @GuardantHealth]

We’re excited to share that we've been recertified as a Great Place To Work® in the U.S. for the fourth year in a row — a reflection of the people, purpose, and culture that drive us forward every day as we work to conquer cancer with data.

#ThankYou to everyone across Guardant® whose passion, dedication, and collaboration make this recognition possible.

[Guardant Health @GuardantHealth]

#Leadership today is defined by more than outcomes.

Later today, our co-CEO AmirAli Talasaz joins leaders at the @MilkenInstitute Global Conference for an invite-only discussion on how reputation, trust, and culture are shaping resilient organizations.

#MIGlobal session details: https://t.co/PgWzRHYwgq

[Guardant Health @GuardantHealth]

The next wave of health innovation is already taking shape.

This afternoon, our Chairman and co-CEO Helmy Eltoukhy will join leaders at the @MilkenInstitute Global Conference to discuss the technologies redefining what’s possible in healthcare—from AI-enabled discovery to multimodal data platforms and next-generation diagnostics.

Turning these advances into impact will require clarity across regulation, sustainable models for access, and continued investment in innovation.

Watch the #MIGlobal session live: https://t.co/yMOWsjOYpd

[Guardant Health @GuardantHealth]

We’re proud to share the FDA’s approval of Guardant360® CDx as a companion diagnostic for VEPPANU (vepdegestrant) for patients with ER+/HER2- advanced #BreastCancer with ESR1 mutations, marking our third ESR1 companion diagnostic FDA approval.

Details: https://t.co/uhW135jeZ8

[Guardant Health @GuardantHealth]

Strong alignment across healthcare leaders is how innovation reaches patients faster.

At the @USChamber 2026 Health Summit, our Co-CEO AmirAli Talasaz shared why the pace of innovation—from genomics to AI—is accelerating, and what it will take to ensure access keeps up with the science.

When policy and innovation move together, the impact for patients is real.

[U.S. Chamber @USChamber]

A panel of healthcare industry CEOs discussed how C-suite leaders are aligning and driving innovation across the healthcare ecosystem to modernize America’s health system and improve patient outcomes.

“The State of the Union of innovation in this country is very strong,” said AmirAli Talasaz, Co-CEO, Guardant Health. “Based on the trends that we are seeing, for instance, genome sequencing, AI, advanced radiology and imaging, some surgical interventions, medical devices. The future could be very bright for patients.”

[Guardant Health @GuardantHealth]

A collaboration shaped by the expanding role of precision diagnostics in oncology drug development.

Today, we announced a multi-year collaboration with @nuvalent to advance clinical development and companion diagnostic strategies using the tissue and liquid offerings of our Guardant Infinity™ platform.

Details: https://t.co/Hlqimm5hD8

[Guardant Health @GuardantHealth]

#ColorectalCancer screening isn’t just a clinical conversation. It’s a community one.

In our latest blog, we share how we’re partnering with the First Ladies Health Initiative to bring that critical conversation forward through trusted voices and real stories that empower people to take control of their health.

Because when awareness meets trust, more people take action.

Read more: https://t.co/Owoqczl11X

[Guardant Health @GuardantHealth]

Join us for a live clinical education #Webinar exploring how emerging ctDNA evidence may reshape management of HR+/HER2- metastatic #BreastCancer. Guardant Health clinical leadership & expert oncologists will discuss insights from the SERENA-6 trial and the evolving role of ESR1 monitoring in treatment decision-making.

📅 Date: Wednesday, April 15
🕚 Time: 11:00am PT

Register today: https://t.co/GRhMd0Eigc